Trial
NCT03707457
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Bristol-Myers Squibb
Condition
Glioblastoma
Intervention
Nivolumab
Why stopped
Funding/material support withdrawn
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-02